

FOR IMMEDIATE RELEASE

For More Information, Contact:
R. Kelly Schwalbe at 816-474-3166



Boehringer Ingelheim Receives APHIS Approval on new Circovirus Vaccine

ST. JOSEPH, Mo. (October 23, 2006) – Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces that it has received approval from the U.S. Animal and Plant Health Inspection Service for a new vaccine called Ingelvac® CircoFLEX™ to protect swine against diseases caused by porcine circovirus type 2 (PCV2).

According to Klaas Okkinga, marketing manager for BIVI, Ingelvac CircoFLEX is a single-dose, 1 ml vaccine that provides the highest level of efficacy and safety to pigs. “It’s highly effective in immunizing pigs as young as 3 weeks of age prior to exposure to PCV2, and provides long-lasting protection without the systemic irritation and tissue reactions some vaccines can cause.”

In addition, Ingelvac CircoFLEX has a short 21-day withdrawal period and positive pork quality assurance benefits that are important to producers, Okkinga adds. “It has been thoroughly field tested and we are confident this vaccine will help producers more effectively prevent porcine circovirus associated disease.”

Ingelvac CircoFLEX will be widely available to producers in 2007.

For more information on new Ingelvac CircoFLEX vaccine for PCV2, as well as the diagnosis and management of porcine circovirus associated disease, contact Boehringer Ingelheim Vetmedica, Inc., at 800-325-9167.

2621 N. Belt Highway
St. Joseph, Missouri
64506-2002
Toll Free 1-800-821-7467

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of
Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of
the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 143
affiliates in 47 countries and nearly 37,500 employees. Since it was founded in
1885, the family-owned company has been committed to researching,
developing, manufacturing and marketing novel products of high therapeutic
value for human and veterinary medicine.

In 2005, Boehringer Ingelheim posted net sales of US \$11.8 billion (9.5 billion
euro) while spending nearly one-fifth of net sales in its largest business segment,
Prescription Medicines, on research and development.

For more information, please visit www.bi-vetmedica.com.

###